CSIMarket
 


Pfizer Inc  (PFE)
Other Ticker:  
 

Cumulative Pfizer Inc's Long Term Debt to Equity for Trailing Twelve Months Period

PFE's Long Term Debt to Equity for Trailing Twelve Months Period and Long Term Debt, Equity growth


Select the Comparisons : Select the Ratio:

PFE Long Term Debt to Equity for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Oct 01 2023)
III. Quarter
(Jul 02 2023)
II. Quarter
(Apr 02 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Growth -6.91 % 4.64 % 13.52 % 22.44 % 23.82 %
Y / Y Long Term Debt Growth 87.14 % 87.1 % 78.91 % -11.08 % -9.15 %
Long Term Debt to Equity for Trailing Twelve Months Period 0.56 0.48 0.41 0.35 0.38
Total Ranking # 1081 # 1464 # 1385 # 1318 # 1551
Seq. Equity Growth -8.14 % -2.1 % -1.92 % 5.55 % 3.26 %
Seq. Long Term Debt Growth 0.8 % -0.5 % 93.53 % -3.59 % 0.78 %


Long Term Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to net new long-term borrowings of 0.8%, Long Term Debt to Equity for Trailing Twelve Months Period improved to 0.56, above Pfizer Inc's average Long Term Debt to Equity for Trailing Twelve Months Period.
Long Term Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 49 other companies have achieved lower Long Term Debt to Equity for Trailing Twelve Months Period than Pfizer Inc. While total ranking remained unchanged compare to previous quarter at no. .

What is Long Term Debt to Equity Ratio?
What is PFE selling?
Long Term Debt to Equity PFE in the most recent quarter
Long Term Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 50
Sector # 139
S&P 500 # 1223


Long Term Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.67 0.38 0.08
(Dec 31 2020)   (March 31, 2007)




Companies with similar average Long Term Debt to Equity for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to Equity for Trailing Twelve Months Period
Zoetis Inc   1.38 
Ionis Pharmaceuticals Inc  1.38 
Lucy Scientific Discovery Inc   1.37 
G1 Therapeutics Inc   1.34 
Bristol myers Squibb Company  1.14 
Corbus Pharmaceuticals Holdings Inc   1.12 
Tg Therapeutics Inc   1.06 
Spectrum Pharmaceuticals Inc   1.05 
Catalent Inc   1.04 
Tempest Therapeutics Inc   0.99 
Milestone Pharmaceuticals inc   0.88 
Axsome Therapeutics Inc   0.85 
Elanco Animal Health Inc  0.84 
Prestige Consumer Healthcare Inc   0.83 
Viatris Inc   0.83 
Perrigo Company Plc  0.82 
Cerevel Therapeutics Holdings Inc   0.82 
Mustang Bio inc   0.82 
Marinus Pharmaceuticals Inc   0.81 
Ani Pharmaceuticals Inc  0.77 
Vbi Vaccines Inc  0.76 
Innoviva Inc   0.76 
Avid Bioservices Inc   0.76 
Aptinyx Inc   0.73 
Cryoport inc   0.73 
Coya Therapeutics Inc   0.73 
Merck and Co Inc   0.72 
Pacira Biosciences inc   0.72 
Journey Medical Corporation  0.71 
Petros Pharmaceuticals inc   0.68 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com